Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.
See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.
Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.
Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.
Explore essential insights on batch release processes to enhance compliance and quality. Dive into our article for practical guidance and best practices.

| TITLE/ COMPANY | Issue Date | Status | Details |
|---|---|---|---|
| A Form FDA 483 Inspectional Observations was issued at the conclusion of the inspection. ModernaTX, Inc. |
05 Aug 2026 | Normal | Justification: The process of receiving, responding, and resolving FDA 483 observations inherently involves audit management skills. Excerpt: The firm responded to the observations, and the corrective actions were reviewed and found to be adequate. View Details |
| Pre-License Inspection #1 Vascular Solutions, LLC |
29 Jun 2026 | Normal | Justification: Pre-License Inspection #1 implies serious gaps in audit management, considering the volume of observations. Excerpt: Form FDA 483 issued with 14 observations View Details |
| Your firm lacks adequate quality oversight to ensure Acceptable Quality Level (AQL) samples are taken Hospira, Inc. |
10 Mar 2026 | Normal | Justification: As per SOP-96072, auditing is a control point for sampling adherence but failed, necessitating process audit improvement. Excerpt: Auditing of Production Operations, Section E.3 clarifies representation requirement, suggesting auditing lapses contributed. View Details |
| Internal audits have not been conducted at planned intervals Bear-Ent, Llc |
26 Feb 2026 | Normal | Justification: Audit Management process crucial as the audit schedule's absence directly links to lapses in systematic risk assessments. Excerpt: No internal audits or audit schedules have been completed for 2023, 2024, and 2025. View Details |
| Internal audits have not been adequately conducted at planned intervals to determine whether the QMS Seniorlife Technologies Inc |
20 Feb 2026 | Normal | Justification: Audit Management is implicated due to non-compliance with documented audit procedures and incomplete audit coverage. Excerpt: Your firm does not adhere to the requirement that each organization shall document procedures for quality audits. View Details |
View and learn more about FDA Inspections
with our comprehensive list of resources